Long-term intrathecal ziconotide therapy: A case study and discussion

Neuromodulation

Volumn 4, Issue 3, 2001, Pages 121-126

  Staats, Peter S ^a   Luthardt, Frederick ^a   Shipley, Jane ^a   Jackson, Catherine ^a   Fischer, Karl ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chronic pain; Intrathecal pain therapy; Neuropathic pain; Neurotoxin

Indexed keywords

OMEGA CONOTOXIN MVIIA; PLACEBO;

ADULT; ALLODYNIA; ANALGESIA; ARTICLE; CASE REPORT; CHRONIC PAIN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; HUMAN; LONG TERM CARE; MALE; PAIN THRESHOLD; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL;

EID: 0034932247     PISSN: 10947159     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1403.2001.00121.x     Document Type: Article

References (17)

1. Chronic musculoskeletal pain and depression symptoms in the National Health and Nutrition Examination. I. Epidemiological Follow-up Study
2. Intraspinal infusion devices
3. Intrathecal infusional analgesia for nonmalignant pain: Analgesic efficacy of intrathecal opioid with or without bupivacaine
4. Intrathecal morphine in chronic pain management: In reply
5. Peptide neurotoxins from fish-hunting cone snails
6. Antogonists of neuronal calcium channels: Structure and therapeutic implications
7. Neuronal calcium channel antagonists. Discrimination between calcium channel subtypes using omega-conotoxin from Conus Magus venom
8. Characterization of the binding of ω-conopeptides to different classes of non L-type neuronal calcium channels
9. The validation of the visual analogue scale as ratio scale measures for chronic and experimental pain
10. Pharmacokinietics of SNX-111, a selective N-type calcium channel blocker, in rats and cynomolgus monkeys
11. Sympatholysis after neuron-specific, N-type, voltage sensitive calcium channel blockers: First demonstration of N-channel function in humans
12. Adverse effects associated with the intrathecal administration of ziconotide
13. The powerful placebo: Friend or foe?
14. Placebo response in chronic malignant and nonmalignant pain